Menu
← Oncology Approval Tracker
FDA DECISION ·
Tukysa + trastuzumab + pertuzumab
tucatinib with trastuzumab and pertuzumab · Seagen / Pfizer
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Maintenance for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
LAMPGEN ANALYSIS
Why it matters
This adds tucatinib to HER2-directed maintenance. The evidence applies to the handoff after induction, with eligibility in HER2CLIMB-05 requiring no progression after the induction regimen.
What research teams should watch
Document completed induction cycles, post-induction imaging and any brain metastases. That handoff determines whether maintenance evidence maps to an individual patient.
PRIMARY RECORDS